Vitezslav Vylicil/iStock via Getty Images
- Processa Pharmaceuticals (NASDAQ:PCSA) lost ~16% on Wednesday after the drug developer disclosed feedback it received from the FDA regarding a mid-stage trial for its chemotherapy candidate, Next Generation Capecitabine (NGC-Cap).
- After a meeting with the agency, the Hanover, Maryland-based pharma said it would continue